<p>/PRNewswire/ -- 根据 Mordor Intelligence 的报告，全球伴随诊断市场在 2025 年的估值为 87 亿美元，预计到 2030 年将超过 156.2 亿美元，预测期内（2025–2030 年）年均增长率为 12.42%。市场主要受精准医疗在肿瘤学和罕见疾病中的应用增长，以及基于生物标志物的检测需求增加的推动，以提高药物的有效性和安全性。</p>
<p><strong>区域细分洞察</strong></p>
<p><strong>北美</strong> 继续主导伴随诊断市场，得益于强大的制药管道、良好的报销政策以及分子检测技术的早期采用。该地区 FDA 对药物和诊断共同开发的监管明确性也简化了商业化路径。</p>
<p><strong>亚太地区</strong> 正在成为增长最快的地区，受癌症负担增加、基因检测服务扩展以及中国、日本和印度本地化诊断解决方案快速发展的推动。国家层面的精准医疗整合到医疗系统的倡议进一步增强了区域需求。</p>
<p><strong>塑造市场动态的主要趋势</strong></p>
<p><strong>对精准和靶向疗法的需求上升</strong></p>
<p>对个性化医疗的日益重视正在重塑治疗范式。制药公司越来越依赖伴随诊断来根据基因或分子特征识别患者亚组。这一趋势在肿瘤学中尤为明显，伴随诊断指导靶向疗法的使用，如 EGFR、HER2 和 PD-L1 抑制剂。</p>
<p><strong>下一代测序（NGS）技术的整合</strong></p>
<p>基于 NGS 的检测平台正在改变我们发现生物标志物和进行多重检测的方式。通过实现对多种突变的全面基因组分析，NGS 有助于减少周转时间和每个样本的成本。这项技术也正在超越肿瘤学，在传染病、神经学和心血管研究中找到新的应用。</p>
<p><strong>制药公司与诊断开发商之间的战略合作</strong></p>
<p>制药和诊断公司越来越多地形成战略联盟，以共同开发伴随诊断与药物管道。这些合作有助于协调监管提交，加快市场进入时间。此外，AI 和生物信息学工具的整合正在改善复杂基因组数据的解读，支持更快的临床决策。</p>
<p><strong>综合细分概述</strong></p>
<p><strong>按技术</strong></p>
<ul>
<li>聚合酶链反应（PCR）</li>
<li>免疫组化（IHC）</li>
<li>实时 PCR（RT-PCR）</li>
<li>原位杂交（ISH）</li>
<li>下一代测序（NGS）</li>
<li>其他技术</li>
</ul>
<p><strong>按适应症</strong></p>
<ul>
<li>肺癌</li>
<li>乳腺癌</li>
<li>结直肠癌</li>
<li>白血病</li>
<li>黑色素瘤</li>
<li>胃癌</li>
<li>前列腺癌</li>
<li>其他适应症</li>
</ul>
<p><strong>按产品和服务</strong></p>
<ul>
<li>检测和试剂盒</li>
<li>仪器和分析仪</li>
<li>软件和服务</li>
</ul>
<p><strong>按样本类型</strong></p>
<ul>
<li>组织活检</li>
<li>液体活检</li>
<li>细胞学涂片</li>
</ul>
<p><strong>按最终用户</strong></p>
<ul>
<li>制药和生物技术公司</li>
<li>临床参考实验室</li>
<li>合同研究组织（CRO）</li>
<li>医院和癌症中心</li>
</ul>
<p><strong>按地区</strong></p>
<ul>
<li>北美</li>
<li>欧洲</li>
<li>亚太地区</li>
<li>中东和非洲</li>
<li>南美</li>
</ul>
<p><strong>有关市场规模、细分数据和竞争情报的完整信息，请访问 Mordor Intelligence 报告的详细信息：</strong></p>
<p>https://www.mordorintelligence.com/industry-reports/companion-diagnostics-market?utm_source=prnewswire</p>
<p><strong>战略市场格局</strong></p>
<p>伴随诊断市场适度集中，全球诊断制造商、生物技术公司和技术提供商积极推进共同开发合作伙伴关系和多重检测解决方案。市场领导者专注于在多个癌症适应症中扩展伴随检测，并投资于获得监管批准的 NGS 面板。</p>
<p><strong>领先的伴随诊断公司</strong></p>
<ul>
<li>Qiagen NV</li>
<li>Agilent Technologies Inc.</li>
<li>Abbott</li>
<li>bioMérieux</li>
<li>F. Hoffmann-La Roche Ltd</li>
</ul>
<p><strong>查看 Mordor Intelligence 发布的相关报告：</strong></p>
<p><strong>肿瘤分子诊断市场</strong>：肿瘤分子诊断市场报告按产品类型（仪器）、技术（聚合酶链反应）、癌症类型（乳腺癌）、样本类型（组织活检等）、最终用户（医院）和地区（北美、欧洲、亚太地区、中东和非洲、南美）进行细分。</p>
<p>Illumina、QIAGEN、Roche、Thermo Fisher Scientific 和 Danaher 是该市场的主要公司。</p>
<p><strong>了解更多活跃于</strong> <strong>肿瘤分子诊断</strong> <strong>的公司：</strong> <strong>https://www.mordorintelligence.com/industry-reports/global-oncology-molecular-diagnostics-market/companies?utm_source=prnewswire</strong></p>
<p><strong>伴随动物诊断市场</strong>：伴随动物诊断市场报告将行业细分为按动物（猫、狗、其他动物）、按应用（细菌学、寄生虫学、临床病理学、其他应用）、按技术（免疫诊断测试、分子诊断、诊断成像、其他诊断）和地区（北美、欧洲、亚太地区、中东和非洲、南美）。</p>
<p>Heska、Neogen、Zoetis、IDEXX 和 Innovative Diagnostics 是该市场的主要公司。</p>
<p><strong>了解更多活跃于</strong> <strong>伴随动物诊断</strong> <strong>的公司：</strong> <strong>https://www.mordorintelligence.com/industry-reports/companion-animal-diagnostic-market/companies?utm_source=prnewswire</strong></p>
<p><strong>解剖病理市场</strong>：解剖病理市场报告按产品和服务（仪器、耗材和服务）、应用（疾病诊断、药物发现与开发及其他应用）、最终用户（医院、诊断实验室）、地区（北美、欧洲、亚太地区、中东和非洲、南美）进行细分。</p>
<p>赛默飞世尔科技、Quest Diagnostics、罗氏、LabCorp 和安捷伦科技是该市场的主要公司。</p>
<p><strong>了解更多关于活跃于</strong> <strong>解剖病理学</strong> <strong>的公司：</strong> <strong>https://www.mordorintelligence.com/industry-reports/anatomic-pathology-market/companies?utm_source=prnewswire</strong></p>
<p><strong>关于 Mordor Intelligence：</strong></p>
<p>Mordor Intelligence 是一家值得信赖的合作伙伴，为寻求全面和可操作市场情报的企业提供服务。我们的全球覆盖、专业团队和量身定制的解决方案使组织和个人能够做出明智的决策，驾驭复杂的市场，实现战略目标。</p>
<p>Mordor Intelligence 拥有超过 550 名领域专家和遍布 150 多个国家的现场专家，对全球商业环境有独特的理解。这种专业知识转化为涵盖航空航天与国防、农业、动物营养与健康、自动化、汽车、化学与材料、消费品与服务、电子、能源与电力、金融服务、食品与饮料、医疗保健、酒店与旅游、信息与通信技术、投资机会和物流等广泛行业的综合性综合和定制研究报告。</p>
<p><strong>如有任何咨询，请联系：</strong></p>
<p>[email protected]</p>
<p>https://www.mordorintelligence.com/contact-us</p>
<p>Logo: https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg</p>
<p>来源：Mordor Intelligence Private Limited</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTA1Jk5ld3NJdGVtSWQ9SU8xNjI3MSZUcmFuc21pc3Npb25fSWQ9MjAyNTExMDUwNTAxUFJfTkVXU19VU1BSX19fX19JTzE2Mjcx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTA1Jk5ld3NJdGVtSWQ9SU8xNjI3MSZUcmFuc21pc3Npb25fSWQ9MjAyNTExMDUwNTAxUFJfTkVXU19VU1BSX19fX19JTzE2Mjcx"/></p>

Ultragenyx制药

<p>全球伴随诊断市场预计将从 2025 年的 87 亿美元增长到 2030 年的 156.2 亿美元，年均增长率为 12.42%，主要受精准医疗在肿瘤学和罕见疾病应用的推动。北美市场领先，而亚太地区是增长最快的区域。主要趋势包括对靶向疗法需求的增加、下一代测序技术的整合，以及制药公司与诊断公司之间的战略合作。主要参与者包括 Qiagen、安捷伦科技和罗氏</p>

<p>, /PRNewswire/ -- According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is projected to surpass USD 15.62 billion by 2030, growing at a CAGR of 12.42% during the forecast period (2025–2030). The market is primarily driven by the growing applications of precision medicine in oncology and rare diseases, and the increasing need for biomarker-based testing to improve drug efficacy and safety.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 根据 Mordor Intelligence 的报告，全球伴随诊断市场在 2025 年的估值为 87 亿美元，预计到 2030 年将超过 156.2 亿美元，预测期内（2025–2030 年）年均增长率为 12.42%。市场主要受精准医疗在肿瘤学和罕见疾病中的应用增长，以及基于生物标志物的检测需求增加的推动，以提高药物的有效性和安全性。</p>
</div><p><strong>Regional Segment Insights</strong></p>
<div class="lb-trans"><p><strong>区域细分洞察</strong></p>
</div><p><strong>North America</strong> continues to dominate the companion diagnostics market, supported by a robust pharmaceutical pipeline, favorable reimbursement policies, and early adoption of molecular testing technologies. The region's regulatory clarity from the FDA for co-development of drugs and diagnostics has also streamlined commercialization pathways.</p>
<div class="lb-trans"><p><strong>北美</strong> 继续主导伴随诊断市场，得益于强大的制药管道、良好的报销政策以及分子检测技术的早期采用。该地区 FDA 对药物和诊断共同开发的监管明确性也简化了商业化路径。</p>
</div><p><strong>Asia-Pacific</strong> is emerging as the fastest-growing region, driven by an increasing cancer burden, expansion of genetic testing services, and the rapid development of localized diagnostic solutions in China, Japan, and India. National initiatives to integrate precision medicine into healthcare systems are further strengthening regional demand.</p>
<div class="lb-trans"><p><strong>亚太地区</strong> 正在成为增长最快的地区，受癌症负担增加、基因检测服务扩展以及中国、日本和印度本地化诊断解决方案快速发展的推动。国家层面的精准医疗整合到医疗系统的倡议进一步增强了区域需求。</p>
</div><p><strong>Major Trends Shaping Market Dynamics</strong></p>
<div class="lb-trans"><p><strong>塑造市场动态的主要趋势</strong></p>
</div><p><strong>Rising Demand for Precision and Targeted Therapies</strong></p>
<div class="lb-trans"><p><strong>对精准和靶向疗法的需求上升</strong></p>
</div><p>The growing emphasis on personalized medicine is reshaping treatment paradigms. Pharmaceutical companies increasingly rely on companion diagnostics to identify patient subgroups based on genetic or molecular profiles. This trend is particularly evident in oncology, where companion diagnostics guide the use of targeted therapies such as EGFR, HER2, and PD-L1 inhibitors.</p>
<div class="lb-trans"><p>对个性化医疗的日益重视正在重塑治疗范式。制药公司越来越依赖伴随诊断来根据基因或分子特征识别患者亚组。这一趋势在肿瘤学中尤为明显，伴随诊断指导靶向疗法的使用，如 EGFR、HER2 和 PD-L1 抑制剂。</p>
</div><p><strong>Integration of Next-Generation Sequencing (NGS) Technologies</strong></p>
<div class="lb-trans"><p><strong>下一代测序（NGS）技术的整合</strong></p>
</div><p>The use of NGS-based testing platforms is transforming how we discover biomarkers and perform multiplex testing. By enabling comprehensive genomic profiling across multiple mutations, NGS helps reduce both turnaround time and cost per sample. This technology is also moving beyond oncology, finding new applications in infectious diseases, neurology, and cardiovascular research.</p>
<div class="lb-trans"><p>基于 NGS 的检测平台正在改变我们发现生物标志物和进行多重检测的方式。通过实现对多种突变的全面基因组分析，NGS 有助于减少周转时间和每个样本的成本。这项技术也正在超越肿瘤学，在传染病、神经学和心血管研究中找到新的应用。</p>
</div><p><strong>Strategic Collaborations Between Pharma and Diagnostic Developers</strong></p>
<div class="lb-trans"><p><strong>制药公司与诊断开发商之间的战略合作</strong></p>
</div><p>Pharmaceutical and diagnostic firms are increasingly forming strategic alliances to co-develop companion diagnostics alongside drug pipelines. These collaborations help align regulatory submissions and accelerate market entry timelines. Additionally, the integration of AI and bioinformatics tools is improving the interpretation of complex genomic data, supporting faster clinical decision-making.</p>
<div class="lb-trans"><p>制药和诊断公司越来越多地形成战略联盟，以共同开发伴随诊断与药物管道。这些合作有助于协调监管提交，加快市场进入时间。此外，AI 和生物信息学工具的整合正在改善复杂基因组数据的解读，支持更快的临床决策。</p>
</div><p><strong>Comprehensive Segmental Overview</strong></p>
<div class="lb-trans"><p><strong>综合细分概述</strong></p>
</div><p><strong>By Technology</strong></p>
<div class="lb-trans"><p><strong>按技术</strong></p>
</div><ul>
<li>Polymerase Chain Reaction (PCR)</li>
<li>Immunohistochemistry (IHC)</li>
<li>Real-Time PCR (RT-PCR)</li>
<li>In Situ Hybridization (ISH)</li>
<li>Next-Generation Sequencing (NGS)</li>
<li>Other Technologies</li>
</ul>
<div class="lb-trans"><ul>
<li>聚合酶链反应（PCR）</li>
<li>免疫组化（IHC）</li>
<li>实时 PCR（RT-PCR）</li>
<li>原位杂交（ISH）</li>
<li>下一代测序（NGS）</li>
<li>其他技术</li>
</ul>
</div><p><strong>By Indication</strong></p>
<div class="lb-trans"><p><strong>按适应症</strong></p>
</div><ul>
<li>Lung Cancer</li>
<li>Breast Cancer</li>
<li>Colorectal Cancer</li>
<li>Leukemia</li>
<li>Melanoma</li>
<li>Gastric Cancer</li>
<li>Prostate Cancer</li>
<li>Other Indications</li>
</ul>
<div class="lb-trans"><ul>
<li>肺癌</li>
<li>乳腺癌</li>
<li>结直肠癌</li>
<li>白血病</li>
<li>黑色素瘤</li>
<li>胃癌</li>
<li>前列腺癌</li>
<li>其他适应症</li>
</ul>
</div><p><strong>By Product &amp; Service</strong></p>
<div class="lb-trans"><p><strong>按产品和服务</strong></p>
</div><ul>
<li>Assays &amp; Kits</li>
<li>Instruments &amp; Analyzers</li>
<li>Software &amp; Services</li>
</ul>
<div class="lb-trans"><ul>
<li>检测和试剂盒</li>
<li>仪器和分析仪</li>
<li>软件和服务</li>
</ul>
</div><p><strong>By Sample Type</strong></p>
<div class="lb-trans"><p><strong>按样本类型</strong></p>
</div><ul>
<li>Tissue Biopsy</li>
<li>Liquid Biopsy</li>
<li>Cytology Smears</li>
</ul>
<div class="lb-trans"><ul>
<li>组织活检</li>
<li>液体活检</li>
<li>细胞学涂片</li>
</ul>
</div><p><strong>By End User</strong></p>
<div class="lb-trans"><p><strong>按最终用户</strong></p>
</div><ul>
<li>Pharmaceutical &amp; Biotechnology Companies</li>
<li>Clinical Reference Laboratories</li>
<li>Contract Research Organizations (CROs)</li>
<li>Hospitals &amp; Cancer Centers</li>
</ul>
<div class="lb-trans"><ul>
<li>制药和生物技术公司</li>
<li>临床参考实验室</li>
<li>合同研究组织（CRO）</li>
<li>医院和癌症中心</li>
</ul>
</div><p><strong>By Geography</strong></p>
<div class="lb-trans"><p><strong>按地区</strong></p>
</div><ul>
<li>North America</li>
<li>Europe</li>
<li>Asia-Pacific</li>
<li>Middle East &amp; Africa</li>
<li>South America</li>
</ul>
<div class="lb-trans"><ul>
<li>北美</li>
<li>欧洲</li>
<li>亚太地区</li>
<li>中东和非洲</li>
<li>南美</li>
</ul>
</div><p><strong>For a full breakdown of market size, segmentation data, and competitive intelligence, access the details of the Mordor Intelligence report:</strong></p>
<div class="lb-trans"><p><strong>有关市场规模、细分数据和竞争情报的完整信息，请访问 Mordor Intelligence 报告的详细信息：</strong></p>
</div><p>https://www.mordorintelligence.com/industry-reports/companion-diagnostics-market?utm_source=prnewswire</p>
<div class="lb-trans"><p>https://www.mordorintelligence.com/industry-reports/companion-diagnostics-market?utm_source=prnewswire</p>
</div><p><strong>Strategic Market Landscape</strong></p>
<div class="lb-trans"><p><strong>战略市场格局</strong></p>
</div><p>The companion diagnostics market is moderately consolidated, with global diagnostics manufacturers, biotechnology companies, and technology providers actively advancing co-development partnerships and multiplex testing solutions. Market leaders focus on expanding companion tests across multiple cancer indications and investing in regulatory-approved NGS panels.</p>
<div class="lb-trans"><p>伴随诊断市场适度集中，全球诊断制造商、生物技术公司和技术提供商积极推进共同开发合作伙伴关系和多重检测解决方案。市场领导者专注于在多个癌症适应症中扩展伴随检测，并投资于获得监管批准的 NGS 面板。</p>
</div><p><strong>Leading Companion Diagnostics Companies</strong></p>
<div class="lb-trans"><p><strong>领先的伴随诊断公司</strong></p>
</div><ul>
<li>Qiagen NV</li>
<li>Agilent Technologies Inc.</li>
<li>Abbott</li>
<li>bioMérieux</li>
<li>F. Hoffmann-La Roche Ltd</li>
</ul>
<div class="lb-trans"><ul>
<li>Qiagen NV</li>
<li>Agilent Technologies Inc.</li>
<li>Abbott</li>
<li>bioMérieux</li>
<li>F. Hoffmann-La Roche Ltd</li>
</ul>
</div><p><strong>Check out related reports published by Mordor Intelligence:</strong></p>
<div class="lb-trans"><p><strong>查看 Mordor Intelligence 发布的相关报告：</strong></p>
</div><p><strong>Oncology Molecular Diagnostics Market</strong>: The Oncology Molecular Diagnostics Market Report is Segmented by Product Type (Instrument), Technology (Polymerase Chain Reaction), Cancer Type (Breast Cancer), Sample Type (Tissue Biopsy, and More), End User (Hospitals), and Geography (North America, Europe, Asia-Pacific, Middle East &amp; Africa, South America).</p>
<div class="lb-trans"><p><strong>肿瘤分子诊断市场</strong>：肿瘤分子诊断市场报告按产品类型（仪器）、技术（聚合酶链反应）、癌症类型（乳腺癌）、样本类型（组织活检等）、最终用户（医院）和地区（北美、欧洲、亚太地区、中东和非洲、南美）进行细分。</p>
</div><p>Illumina, QIAGEN, Roche, Thermo Fisher Scientific and Danaher are the major companies operating in this market.</p>
<div class="lb-trans"><p>Illumina、QIAGEN、Roche、Thermo Fisher Scientific 和 Danaher 是该市场的主要公司。</p>
</div><p><strong>Read more about companies active in</strong> <strong>Oncology Molecular Diagnostics</strong> <strong>:</strong> <strong>https://www.mordorintelligence.com/industry-reports/global-oncology-molecular-diagnostics-market/companies?utm_source=prnewswire</strong></p>
<div class="lb-trans"><p><strong>了解更多活跃于</strong> <strong>肿瘤分子诊断</strong> <strong>的公司：</strong> <strong>https://www.mordorintelligence.com/industry-reports/global-oncology-molecular-diagnostics-market/companies?utm_source=prnewswire</strong></p>
</div><p><strong>Companion Animal Diagnostic Market</strong>: The Companion Animal Diagnostics Market report segments the industry into By Animals (Cats, Dogs, Other Animals), By Application (Bacteriology, Parasitology, Clinical Pathology, Other Applications), By Technology (Immunodiagnostic Tests, Molecular Diagnostics, Diagnostic Imaging, Other Diagnostics), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).</p>
<div class="lb-trans"><p><strong>伴随动物诊断市场</strong>：伴随动物诊断市场报告将行业细分为按动物（猫、狗、其他动物）、按应用（细菌学、寄生虫学、临床病理学、其他应用）、按技术（免疫诊断测试、分子诊断、诊断成像、其他诊断）和地区（北美、欧洲、亚太地区、中东和非洲、南美）。</p>
</div><p>Heska, Neogen, Zoetis, IDEXX and Innovative Diagnostics are the major companies operating in this market.</p>
<div class="lb-trans"><p>Heska、Neogen、Zoetis、IDEXX 和 Innovative Diagnostics 是该市场的主要公司。</p>
</div><p><strong>Read more about companies active in</strong> <strong>Companion Animal Diagnostic</strong> <strong>:</strong> <strong>https://www.mordorintelligence.com/industry-reports/companion-animal-diagnostic-market/companies?utm_source=prnewswire</strong></p>
<div class="lb-trans"><p><strong>了解更多活跃于</strong> <strong>伴随动物诊断</strong> <strong>的公司：</strong> <strong>https://www.mordorintelligence.com/industry-reports/companion-animal-diagnostic-market/companies?utm_source=prnewswire</strong></p>
</div><p><strong>Anatomic Pathology Market</strong>: The Anatomic Pathology Market Report is Segmented by Product &amp; Services (Instruments, Consumables, and Services), Application (Disease Diagnosis, Drug Discovery &amp; Development, and Other Applications), End User (Hospitals, Diagnostic Laboratories), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America).</p>
<div class="lb-trans"><p><strong>解剖病理市场</strong>：解剖病理市场报告按产品和服务（仪器、耗材和服务）、应用（疾病诊断、药物发现与开发及其他应用）、最终用户（医院、诊断实验室）、地区（北美、欧洲、亚太地区、中东和非洲、南美）进行细分。</p>
</div><p>Thermo Fisher Scientific, Quest Diagnostics, Roche, LabCorp and Agilent Technologies are the major companies operating in this market.</p>
<div class="lb-trans"><p>赛默飞世尔科技、Quest Diagnostics、罗氏、LabCorp 和安捷伦科技是该市场的主要公司。</p>
</div><p><strong>Read more about companies active in</strong> <strong>Anatomic Pathology</strong> <strong>:</strong> <strong>https://www.mordorintelligence.com/industry-reports/anatomic-pathology-market/companies?utm_source=prnewswire</strong></p>
<div class="lb-trans"><p><strong>了解更多关于活跃于</strong> <strong>解剖病理学</strong> <strong>的公司：</strong> <strong>https://www.mordorintelligence.com/industry-reports/anatomic-pathology-market/companies?utm_source=prnewswire</strong></p>
</div><p><strong>About Mordor</strong> <strong>Intelligence:</strong></p>
<div class="lb-trans"><p><strong>关于 Mordor Intelligence：</strong></p>
</div><p>Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.</p>
<div class="lb-trans"><p>Mordor Intelligence 是一家值得信赖的合作伙伴，为寻求全面和可操作市场情报的企业提供服务。我们的全球覆盖、专业团队和量身定制的解决方案使组织和个人能够做出明智的决策，驾驭复杂的市场，实现战略目标。</p>
</div><p>With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace &amp; defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals &amp; materials, consumer goods &amp; services, electronics, energy &amp; power, financial services, food &amp; beverages, healthcare, hospitality &amp; tourism, information &amp; communications technology, investment opportunities, and logistics.</p>
<div class="lb-trans"><p>Mordor Intelligence 拥有超过 550 名领域专家和遍布 150 多个国家的现场专家，对全球商业环境有独特的理解。这种专业知识转化为涵盖航空航天与国防、农业、动物营养与健康、自动化、汽车、化学与材料、消费品与服务、电子、能源与电力、金融服务、食品与饮料、医疗保健、酒店与旅游、信息与通信技术、投资机会和物流等广泛行业的综合性综合和定制研究报告。</p>
</div><p><strong>For any inquiries, please contact:</strong></p>
<div class="lb-trans"><p><strong>如有任何咨询，请联系：</strong></p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>https://www.mordorintelligence.com/contact-us</p>
<div class="lb-trans"><p>https://www.mordorintelligence.com/contact-us</p>
</div><p>Logo: https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg</p>
<div class="lb-trans"><p>Logo: https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg</p>
</div><p>SOURCE Mordor Intelligence Private Limited</p>
<div class="lb-trans"><p>来源：Mordor Intelligence Private Limited</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTA1Jk5ld3NJdGVtSWQ9SU8xNjI3MSZUcmFuc21pc3Npb25fSWQ9MjAyNTExMDUwNTAxUFJfTkVXU19VU1BSX19fX19JTzE2Mjcx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=IO16271&amp;Transmission_Id=202511050501PR_NEWS_USPR_____IO16271&amp;DateId=20251105"/></p>

Mordor Intelligence 表示，伴随诊断市场预计到 2030 年将达到 156 亿美元，年均复合增长率为 12.4%